SecBot SecBot
SECBOTREPLAY Home › Report › ABT

ABT · Abbott Laboratories completed the acquisition of Exact Sciences for…

ABBOTT LABORATORIES · 8-K filed Mar 23, 2026 at 08:55 ET

At the news

BULLISHIMPACT 8/10

8-K filed Mar 23, 2026 at 08:55 ET

Abbott Laboratories completed the acquisition of Exact Sciences for $105.00 per share in cash, establishing Abbott as a leader in cancer screening and diagnostics. The deal adds Exact Sciences' portfolio, including Cologuard and Oncotype DX, to Abbott's diagnostics business.

  • Abbott completed the acquisition of Exact Sciences on March 23, 2026
  • Exact Sciences shareholders received $105.00 per share in cash
  • Exact Sciences is now a wholly owned subsidiary of Abbott
  • The deal establishes Abbott as a leader in the $60 billion U.S. cancer screening and precision oncology diagnostics market

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access